Investor Deck Lays Bare Dura Acquisition Financials: $209.5M Revenue, $22.3M EBITDA
ASBP has more than doubled off its 52-week low of $3.309.
Summary
An investor presentation furnished by Aspire Biopharma details the financials of its newly acquired Dura Control Systems subsidiary, including $209.5M in FY2025 revenue and $22.3M in Adjusted EBITDA.
Key Events · M&A and Partnerships · ASBP
-
Dura Financials Revealed
The investor presentation shows Dura generated $209.5M in revenue and $22.3M in Adjusted EBITDA for FY2025, translating to a 10.6% margin. In H1 2026, revenue reached $209.5M with a 10.1% margin.
-
Acquisition Funding Details
The $30M acquisition was funded with $30.0M in cash and a $22.5M senior secured revolving credit facility.
-
Operational Scale Disclosed
Dura operates 11 manufacturing facilities and 2 technical centers, employs roughly 1,700 people, and holds more than 275 patents. Its top-ten customer relationships average 28 years.
-
Strategic Transformation
Aspire is evolving into a holding company with industrial businesses, while retaining its development-stage pharmaceutical platform and caffeine product line.
Analysis · ASBP · Life Sciences
For the first time, the investor presentation offers a detailed financial snapshot of the acquired Dura business, revealing FY2025 revenue of $209.5M and Adjusted EBITDA of $22.3M (10.6% margin). Funding details also emerge: the deal was backed by $30M in cash and a $22.5M senior secured revolving credit facility. These concrete metrics give investors a clear basis to assess the transformative acquisition that closed on August 10, 2026.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASBP was trading at $7.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7M. The 52-week trading range was $3.31 to $1,050.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.